Opportunistic salpingectomy, or the removal of fallopian tubes in women already undergoing another abdominal or gynecological ...

An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...

The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.

A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that adult patients ...

The marathon session, conducted on January 1 from 8 am to 5 pm, was led by Prof Santosh Kumar, head of the urology team.

Led by Prof Santosh Kumar, the urology team at Chandigarh’s PGIMER completes a marathon session of four robotic radical ...

Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. Relmada Therapeutics is preparing to launch a late-stage ...

CHAD Thompson grappled with a silent problem for 20 years – he couldn’t pee properly, and it was a constant source of anxiety ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

A UK-led international clinical trial is recruiting 280 patients to see if the technique to remove cancerous cells could ...